Menveo (Meningococcal Group Y Oligosaccharide Conjugated To Corynebacterium Diphtheriae Crm197 Protein, N. M)

The active ingredient consists of meningococcal polysaccharide antigens linked to the CRM197 protein carrier. This conjugation creates a T‑cell‑dependent response, prompting the immune system to produce high‑affinity antibodies that specifically target the capsular polysaccharides of serogroups A, C, W‑135 and Y, providing long‑lasting protection.

The dosing schedule for Menveo is determined by the prescribing healthcare professional based on the patient’s age, health status and vaccination history. The prescriber will decide the number of doses and the interval between them according to approved guidelines.

Safety data for Menveo in pregnancy are limited. It should only be used when clearly needed and after a risk‑benefit assessment by the healthcare provider. Breastfeeding is not a contraindication, but the prescriber should evaluate any potential risks.

To order Menveo, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials before providing pricing, availability, cold‑chain shipping details and import documentation.

Menveo is a quadrivalent conjugate vaccine covering serogroups A, C, W‑135 and Y, offering T‑cell‑dependent immunity and longer‑lasting protection compared with polysaccharide‑only vaccines. Its conjugate technology generally results in better immune memory and suitability for younger age groups.

Menveo must be stored at 2‑8 °C in a refrigerator. Keep the vials in the original packaging, protect them from light, and do not freeze or shake the product. Once removed from refrigeration, use within the time frame specified in the product labeling.

Menveo is given as an intramuscular injection, typically into the deltoid muscle of the upper arm. The injection is performed by a qualified healthcare professional using aseptic technique. The exact administration schedule depends on the patient’s age and prior vaccination history.

Serious risks, though rare, include anaphylaxis, severe allergic reactions, Guillain‑Barré syndrome, seizures and severe hypotension. Any signs of a severe reaction, such as difficulty breathing, swelling of the face or throat, or a rapid drop in blood pressure, require immediate medical attention.

Menveo should not be given to individuals with a known severe hypersensitivity to any component of the vaccine, including the CRM197 protein carrier. It is also not approved for use in persons older than 55 years. Contraindications and precautions should be reviewed by the prescribing clinician.